An observational study in Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Acute Coronary Syndromes and ST-segment Elevation Myocardial Infarction (STEMI), sponsored by China National Center for Cardiovascular Diseases. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by China National Center for Cardiovascular Diseases · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases — 26 open to participants now, 27 under way, none of them phase 3. Coronary Artery Disease · China National Center for Cardiovascular Diseases.
Among the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases, this one is the 25th largest by enrollment of the 25 observational ones that give a count, is one of 11 that started in 2026, is one of 25 observational ones, and was the 48th registered.
4,861 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →26 of the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+ · Healthy volunteers
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–85
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 588 Coronary Artery Disease studies recruiting now, 403 (69%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 47 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 323 across 1,688 observational studies indexed under Coronary Artery Disease.
Median enrollment 501 across the 32 interventional studies, 460 across the 25 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 270 studies on the registry; 142 are open to participants now.
6 of the studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT06917664China National Center for Cardiovascular DiseasesTreatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease | 2026-12 |
| NCT07660419China National Center for Cardiovascular DiseasesEffect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque | 2026-12-31 |
| NCT06822894China National Center for Cardiovascular DiseasesClinical Implications of Three-vessel Ultrasonic Flow Ratio Measurement in Patients With Coronary Artery Disease | 2026-12-31 |
| NCT06932874China National Center for Cardiovascular DiseasesMetformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease | 2026-12-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether an OCR-LLM-based clinical decision support framework improves clinicians' accuracy in classifying coronary syndrome subtypes from admission history of present illness. Participating clinicians will classify a set of cases first without AI assistance and then with assistance from the OCR-LLM framework. The primary outcome is the change in classification accuracy between unaided and AI-assisted assessments.
The study population includes (1) de-identified clinical encounter records and (2) physician participants for usability testing. For record-based cohorts, eligible encounters contain an admission/presentation History of Present Illness (HPI) (text or image-derived text) sufficient for 4-class coronary syndrome subtyping (e.g., STEMI, NSTEMI, unstable angina, chronic coronary syndrome). Records are analyzed at the encounter level and are organized into five dataset-based cohorts (internal validation, multicenter external validation, ED external validation, English EHR external validation, and clinician usability). Reference labels are assigned using a prespecified clinical adjudication process.
Inclusion Criteria:Hospital encounters with admission HPI documenting sym
2a4afaef-9dc1-47fc-874f-9dffaf7…
evant to coronary syndrome subtyping.
Cases with sufficient documentation to assign one of four target subtypes (STEMI, NSTEMI, UA, CCS) by adjudication.
-
Exclusion Criteria: Unclear subtype or incomplete/uncertain time information preventing gold standard assignment.
Non-CHD primary reason for admission after screening (for MIMIC-IV cohort).
-
Prospective usability evaluation cohort. Physicians complete a structured coronary syndrome subtyping task using admission HPI cases. Outcomes include diagnostic accuracy and time to completion; within-participant comparisons may be performed between unassisted and tool-assisted conditions as prespecified.
Device: OCR-Prompt-LLM Information Extraction and Classification Workflow (OCR-Prompt-LLM) · Device: Manual Clinical Data Review
An automated clinical data management workflow integrating Optical Character Recognition (OCR), optimized prompt engineering, and large language models (LLMs). The system processes unstructured inpatient/ED records (primarily admission history of present illness and related narrative text) to extract prespecified key clinical indicators (e.g., left ventricular ejection fraction, coronary syndrome subtype, medications) and to classify cases into prespecified coronary artery disease categories (e.g., unstable angina, STEMI, NSTEMI, chronic coronary syndrome). The workflow outputs structured fields and a classification result with supporting evidence excerpts.
Standard manual process in which experienced clinicians review patient medical records and extract the same prespecified clinical indicators and coronary artery disease categories using routine clinical judgment and documentation review. This manual abstraction serves as the human benchmark for comparing diagnostic accuracy, completeness, and operational efficiency against the automated OCR-Prompt-LLM workflow.
Overall classification accuracy
Time Frame: Up to completion of dataset evaluation (internal + external cohorts) Description: Proportion of cases with correct subtype (STEMI/NSTEMI/UA/CCS) compared with expert-adjudicated gold standard.
Time frame: 1 month
Plan to share: No — To protect patient privacy and comply with the data management policies of the participating institutions (Fuwai Hospital and sub-centers), individual participant data will not be made publicly available. However, aggregated study results and statistical analyses will be included in the final publication.
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Mar 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →